Dr. Levan Darjania
Chief Science Officer
Dr. Darjania is a seasoned and accomplished R&D professional and program manager with over 26-years’ experience in biotechnology, pharmaceutical drug development (both industry and academia), and a proven track record of success in developing and directing in-house and collaborative R&D programs, and forward-thinking strategic planning capabilities. His research interests include preclinical and clinical R&D, ADME, drug formulation and delivery, pharmacokinetics, toxico-kinetics and bioanalysis, cGLP-IND-enabling studies (Modules 4, 2) for FDA filing. Dr. Darjania is a lead author or co-author of numerous research articles in peer-reviewed journals and presenter or co-presenter at numerous professional conferences and meetings in the U.S. and internationally. Dr. Darjania is also experienced with working with Private Investment Groups to oversee the Global Project Analysis, R&D activities, due diligence process, and scientific communications.
Dr. Levan Darjania held the position of Chief Scientific Officer at Vertical Biosciences and Vice President (Project Analysis and R&D) at MJNA Group, LLC in charge of overseeing global due diligence and research and development in the industrial hemp space in USA, EU, and Latin American countries through its subsidiaries and investment holdings. The Company’s products containing naturally occurring cannabinoids, including cannabidiol (CBD), and other products containing CBD-rich hemp oil are formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries, including dietary supplements, prescription-based hemp oil for sale in countries that have legalized its hemp oil for the treatment of various illnesses and conditions, such as Brazil and Mexico, and skincare products.
Prior to moving into the hemp-based nutraceutical industry, as a Director of DMPK at Wellspring Biosciences, Inc., Dr. Darjania oversaw multiple preclinical (PK/PD), clinical (Phase I) and IND enabling regulatory submissions in the U.S. Dr. Darjania has directly supported the successful advancement of 2-clinical drug candidates (ARS-2102 and KO-947) to IND-enabling and first-in-human studies, and successful due diligence in-licensing one oncology drug candidate.
Previously, Dr. Darjania held scientific and R&D leadership positions of increasing responsibility at Takeda Pharmaceuticals, Intellikine Inc, Cylene Pharmaceuticals, Anadys Pharmaceuticals, and Alerion Biomedical where he supported both preclinical and clinical programs in oncology, metabolic disease, and antiviral (HCV/HIV) areas. He has completed post-doctoral research work at the Department of Molecular Cell and Developmental Biology at The University of Texas at Austin and earned his PhD degree in plant biochemistry from Moscow Institute of Biochemistry at The Science Academy of ex-USSR.
“Science and R&D are critical to global competitiveness and Green Hygienics is focused to become the leader in the hemp industry on this front, differentiated from its peers, in order to take the development of the hemp plant and its applications to the next level. With Dr. Darjania’s rich R&D experience combined with his passion for hemp-derived bioactive substances, there was no better choice when it came time to name a Chief Scientific Officer.” – said Mr. Ron Loudoun, CEO of Green Hygienic Holding, Inc.